To date, approximately seven PD‐1/PD‐L1‐targeting drugs are approved for over nine cancers (Figure 2), with many other inhibitors currently under development and or in clinical trials (> 1500 at current standing; https://clinicaltrials.gov). The gene discussed is PDCD1; the disease is cancer.